Alkem Laboratories (NSEI:ALKEM) Price Target Increased by 21.34% to 4,949.93

The average one-year price target for Alkem Laboratories (NSEI:ALKEM) has been revised to 4,949.93 / share. This is an increase of 21.34% from the prior estimate of 4,079.42 dated January 16, 2024.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 3,548.13 to a high of 7,119.00 / share. The average price target represents a decrease of 8.67% from the latest reported closing price of 5,419.60 / share.

Alkem Laboratories Maintains 0.46% Dividend Yield

At the most recent price, the company's dividend yield is 0.46%.

Additionally, the company's dividend payout ratio is 0.19. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.

The company's 3-Year dividend growth rate is -0.11%.

What is the Fund Sentiment?

There are 44 funds or institutions reporting positions in Alkem Laboratories. This is an increase of 3 owner(s) or 7.32% in the last quarter. Average portfolio weight of all funds dedicated to ALKEM is 0.17%, a decrease of 15.17%. Total shares owned by institutions increased in the last three months by 0.37% to 1,266K shares.

What are Other Shareholders Doing?

IN:ALKEM / Alkem Laboratories Limited Shares Held by Institutions

VEIEX - Vanguard Emerging Markets Stock Index Fund Investor Shares holds 343K shares representing 0.29% ownership of the company. No change in the last quarter.

VGTSX - Vanguard Total International Stock Index Fund Investor Shares holds 332K shares representing 0.28% ownership of the company. No change in the last quarter.

INDAX - ALPS holds 104K shares representing 0.09% ownership of the company. In it's prior filing, the firm reported owning 109K shares, representing a decrease of 4.98%. The firm decreased its portfolio allocation in ALKEM by 3.16% over the last quarter.

Morgan Stanley India Investment Fund holds 84K shares representing 0.07% ownership of the company. In it's prior filing, the firm reported owning 119K shares, representing a decrease of 40.65%. The firm decreased its portfolio allocation in ALKEM by 30.77% over the last quarter.

DFCEX - Emerging Markets Core Equity Portfolio - Institutional Class holds 75K shares representing 0.06% ownership of the company. No change in the last quarter.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.